CatSci Launch SmartPath - An Innovative Digital API Risk Assessment

CatSci Ltd are incredibly proud to announce the launch of SmartPath – an innovative digital tool 
created by CatSci that will risk assess our customers’ API, project, and formulation data and offer
them smart mitigation strategies. 

With the premium SmartPath feature, you will work alongside our Director of Material Sciences, Dr 
Robert Dennehy, to devise a tailored life-cycle plan of your API to meet your budget and project 
needs. So, you can focus on what matters most - delivering your asset to the next step, without 
surprises or delays. 

De-risking your pharmaceutical pipeline is our mission, and SmartPath is here to make that a reality.

Dr Robert Dennehy said: “At CatSci, we are very excited about SmartPath. In late development, it’s 
very common to firefight problems created through poor decisions around the API and formulation. 
The paradox is that we very often know the characteristics of projects that might turn into ‘problem 
children.’ SmartPath is a way of collating this information so it becomes directional and can be used 
rather than just ignored. SmartPath helps identify risks and their mitigations that are appropriate for 
the development phase of the drug.”

To celebrate the launch of SmartPath, we are hosting a free virtual symposium on 21st June 2022, 
where we are excited to share more about the digital tool.

The event is titled “A Medicine Is More Than A Molecule” and will explore the crucial role that 
material science and solid-state properties of pharmaceutical materials play in success, as well as 
how SmartPath can help you rapidly take the right steps to accomplish your project objectives.

You can find the agenda here.

Register for the free virtual event today.

© CatSci Ltd, 2022. 

For more information, including media enquiries, please contact: 
CatSci Ltd 
Caitlin Bourton 
Tel: +44 330 025 0170 
Email: caitlin.bourton@catsci.com